Imatinib belongs to the drug class called BCR-ABL tyrosine kinase inhibitors.Imatinib gained FDA approval on May 10, 2001, under the brand name Gleevec. A generic Gleevec is available known as imatinib mesylate. Imatinib is also available under the brand name Imkeldi which is an oral solution....
Imatinib mesylate directly impairs class switch recombination through down-regulation of AID: its potential efficacy as an AID suppressor. Blood 2012;119(13):3123-3127.Imatinib mesylate directly impairs class switchrecombination through through downregulation of AID: its potential efficacy as an AID...
甲磺酸伊马替尼(Imatinib mesylate)由诺华(Novartis)研发,首先于2001年5月10日获美国食品药品管理局(FDA)批准上市,之后于2001年11月7日获欧洲药物管理局(EMA)批准上市,于2005年3月9日获日本医药品医疗器械综合机构(PMDA)批准上市。由诺华在美国上...
导读:甲磺酸伊马替尼由诺华(Novartis)研发,首先于2001年5月10日获美国食品药品管理局(FDA)批准上市,之后于2001年11月7日获欧洲药物管理局(EMA)批准上市,于2005年3月9日获日本医药品医疗器械综合机构(PMDA)批准上市。由诺华在美国上市销售(商品名:Gleevec)。 甲磺酸伊马替尼((Imatinib mesylate)由诺华(Novartis)研...
It is also suggest that imatinib mesylate is the potential drug for clinical usage as AID suppressor, which deregulation of CSR and SHM with the genomic instability is observed in many B cell malignancy. Disclosures No relevant conflicts of interest to declare. 展开 ...
Our Gleevec Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication. Description for Gleevec Imatinib is a small molecule kinase inhibitor. Gleevec film-coated tablets contain imatinib mesylate equivalent to 100 mg or...
::: Imatinib Mesylate 甲磺酸伊马替尼 :::伊马替尼(Imatinib)是一种用于治疗费城染色体(Bcr-Abl)阳性的慢性骨髓性白血病(CML)成人患者的口服药物，伊马替尼(imatinib)是酪氨酸激酶抑制剂，能选择性地抑制慢性髓细胞白血病(CML)患者Bcr-Abl蛋白的酪氨酸激酶活性，从而阻断多条信号传导途径，达到治疗白血病...
The meaning of IMATINIB is an anticancer drug taken orally in the form of its mesylate C29H31N7O·CH4O3S to treat chronic myelogenous leukemia and metastatic or unresectable gastrointestinal stromal tumors.
imatinib mesylate tablets 药品简介 伊马替尼,商品名格列卫,是一种口服的酪氨酸激酶抑制剂类药物,是治疗慢性髓性白血病(cml)的一线用药,能使 cml 患者的 10 年生存率达 85%~90%,大大延长了患者的生命周期,被誉为「慢粒白血病救命药」。甲磺酸伊马替尼胶囊于 2001 年 5 月在美国上市,同年 11 月在欧洲上市,...
Imatinib mesylate is a relatively new drug that targets the BCR-ABL chimeric protein, the molecular basis of chronic myeloid leukemia (CML). A phase II cl... Y Morishima,M Ogura,M Nishimura,... - 《International Journal of Hematology》 被引量: 72发表: 2004年 加载更多来源...